Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sodium Intake in Chronic Kidney Disease (STICK) (STICK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02458248
Recruitment Status : Unknown
Verified September 2018 by Dr Andrew Smyth, University College Hospital Galway.
Recruitment status was:  Active, not recruiting
First Posted : June 1, 2015
Last Update Posted : September 10, 2018
Sponsor:
Collaborators:
Health Research Board, Ireland
National University of Ireland, Galway, Ireland
Information provided by (Responsible Party):
Dr Andrew Smyth, University College Hospital Galway

Brief Summary:
Chronic kidney disease, which affects an estimated 300,000 people in Ireland and over 50 million people in the developed world, is responsible for a considerable burden of premature mortality and morbidity. All patients with chronic kidney disease are recommended low salt diets, i.e. less than a teaspoon of salt per day (which is <5-6g of salt, which contains <2-2.3g of sodium). The average intake in the general population is double the recommended intake, between 1-2 teaspoons per day, which is considered 'moderate' intake. In patients with hypertension, reducing from moderate (average) to low intake is associated with a small reduction in blood pressure. However, achieving this low target salt intake is difficult, and can have a negative knock-on effect on other healthy dietary factors and kidney hormones. In addition, there is no convincing research to show that patients with chronic kidney disease and normal blood pressure benefit from low salt intake. In fact, the small amount of research that does exist shows that the change in kidney function is the same in people who consume low salt diets (<1 teaspoon) and moderate (1-2 teaspoons=average intake) salt diets. Moreover, there are some small studies that report that low-salt diets may increase the risk of death due to heart disease. Given that all patients with chronic kidney impairment are recommended a low-salt diet, it is important that we confirm that this recommendation truly benefits patients. In this randomized controlled trial, we hope to determine whether recommending a low salt intake, compared to average/moderate intake, is associated with a slower rate of decline in kidney function in patients with chronic kidney impairment. The results of this study will provide information to guide future research that will have critical implications for management of patients with chronic kidney disease.

Condition or disease Intervention/treatment Phase
Kidney Diseases Renal Insufficiency, Chronic Renal Insufficiency Behavioral: Sodium Reduction Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial
Study Start Date : March 2016
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Sodium Reduction
In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
Behavioral: Sodium Reduction
In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.

No Intervention: Usual care
For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.



Primary Outcome Measures :
  1. Change in 24-hour urinary creatinine clearance from baseline to final follow-up, measured from 24-hour urinary collection and corresponding serum creatinine measurement at randomisation and final visit. [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Change in eGFR (MDRD formula) from baseline to final follow-up [ Time Frame: 24 months ]
  2. Change in eGFR (CKD-EPI formula) from baseline to final follow-up [ Time Frame: 24 months ]
  3. Rates of requirement for renal replacement therapy [ Time Frame: 24 months ]
  4. Change in 24-hour urinary protein from baseline to final visit [ Time Frame: 24 months ]
  5. Increase in risk category for prognosis of CKD as measured by the KDIGO 2012 CKD classification table [ Time Frame: 24 months ]
  6. Change in 24-hour urinary sodium excretion from baseline to final visit [ Time Frame: 24 months ]
  7. Change in mean systolic and diastolic blood pressure from 24-hour ambulatory blood pressure monitoring completed at baseline and final visit [ Time Frame: 24 months ]
  8. Composite outcome of change in risk category for prognosis of CKD (increase in risk), requirement for renal replacement therapy or death as measured by the KDIGO 2012 CKD classification table [ Time Frame: 24 months ]
  9. Change in functional status as measured by the assessment functional status questionnaire [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 40 years or older
  • MDRD eGFR of 30-60ml/min/1.73m2 on ≥2 occasions ≥3 months apart
  • Most recent eGFR measurement within 3 months Systolic blood pressure <160mmHg and diastolic blood pressure <95mmHg on three office blood pressure readings at time of screening and confirmed by a study ABPM before randomisation of <150/90mmHg
  • No change in anti-hypertensive or diuretic medications (including dose) for 3 months before screening visit
  • Consumption of moderate sodium intake at screening, defined as an estimated daily sodium intake of >2.3g/day estimated from food frequency questionnaire (FFQ) completed during the screening visit
  • Self-reported willingness to modify dietary intake over sustained period, and adhere to directed recommendations over 2 years
  • Signed written informed consent

Exclusion Criteria:

  • Acute Kidney Injury in the preceding three months, defined as doubling of baseline serum creatinine or rapidly declining eGFR over the preceding six months, defined as a decline in eGFR of ≥10ml/min/1.73m2 in those with established CKD
  • Any of the following renal conditions: glomerular disease due to post-infectious glomerulonephritis, IgA nephropathy, thin basement membrane disease, Henoch-Schonlein purpura, proliferative glomerulonephritis, membranous nephropathy (including lupus nephritis), rapidly progressive glomerulonephritis, minimal change disease, or focal segmental glomerulosclerosis
  • Prior or planned renal transplantation
  • Prior, current or planned renal dialysis
  • Medical diagnosis known to be associated with abnormal renal sodium excretion, including Bartter syndrome, SIADH, diabetes insipidus, or serum sodium <125mmol
  • Severe heart failure (defined as left ventricular ejection fraction ≤30% or NYHA Class III/IV symptoms)
  • High-dose loop or thiazide diuretic therapy, exceeding a total daily dose of frusemide 80mg, bumetanide 2mg, hydrochlorothiazide 50mg, bendroflumethiazide 2.5mg, indapamide 2.5mg, metolazone 2.5mg or the use of both a loop and thiazide diuretic
  • Current use of non-steroidal anti-inflammatory drugs (NSAIDs) for 3 or more days per week. Low-dose aspirin <100mg/day is not an exclusion
  • Unable to follow educational advice of the research team
  • Prescribed high-salt diet, low-salt diet or sodium bicarbonate
  • Symptomatic postural hypotension or receiving treatment for postural hypotension
  • Current or recent use (within one month) of immunosuppressive medications including tacrolimus, cyclosporine, azathioprine or mycophenolate mofetil
  • Pregnancy or lactation
  • Unable to comply with 24-hour urinary collections, or medical condition making collection of 24-hour urinary collection difficult (e.g. severe urinary incontinence)
  • Participant unlikely to comply with study procedures or follow-up visits due to severe co-morbid illness or other factor (e.g. inability to travel for follow-up visits, drug or alcohol misuse) in opinion of research team
  • Cognitive impairment defined as a known diagnosis of dementia, or inability to provide informed consent due to cognitive impairment in the opinion of the investigator
  • Body Mass Index (BMI) <20kg/m2 or BMI>40kg/m2
  • Participating in another clinical trial or previous allocation in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02458248


Locations
Layout table for location information
Ireland
HRB Clinical Research Facility Galway
Galway, Ireland
Sponsors and Collaborators
University College Hospital Galway
Health Research Board, Ireland
National University of Ireland, Galway, Ireland
Investigators
Layout table for investigator information
Principal Investigator: Martin J O'Donnell, MB PhD MRCPI National University of Ireland Galway
Principal Investigator: Andrew Smyth, MB PhD National University of Ireland Galway
Layout table for additonal information
Responsible Party: Dr Andrew Smyth, Dr., University College Hospital Galway
ClinicalTrials.gov Identifier: NCT02458248    
Other Study ID Numbers: HRBCRFG-170415-AS
First Posted: June 1, 2015    Key Record Dates
Last Update Posted: September 10, 2018
Last Verified: September 2018
Keywords provided by Dr Andrew Smyth, University College Hospital Galway:
Chronic Kidney Disease
Sodium Reduction
eGFR 30-60ml/min/1.73m2
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Urologic Diseases